🔎 #TacticalTrendsThursday Week 7:
40 drugs reimbursed in 🇮🇪 in 2024.
Avg. timeline: 580 days
⏱️ Faster, yes—but still nearly 2 years to access.
Progress is real, but high-need therapies can’t afford to wait.

#MarketAccess #HTA #Reimbursement #IrishHealthcare #SalutemInsights

🔎 #TacticalTrendsThursday Week 6
The HSE Drugs Group is assessing more meds—but delays are growing.
⏳ Avg. 8 months to first meeting
📈 MAPs rising
🚪 Impacts access & strategy
See infographics for more detail👇

#MarketAccess #HTA #HSEDrugsGroup #SalutemInsights

🔎 #TacticalTrendsThursday Week 2 🔎
At Salutem Insights, we track every medicine through the full Irish reimbursement process. What’s changing in 2024? 📉 Lower submission volumes, 📊 More complex HTAs, 🎗️ Oncology still leads.
For more insights: bit.ly/SILinkedIn
#SalutemInsights #MarketAccess #HTA